Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Dow
Express Scripts
Moodys
McKinsey

Last Updated: February 7, 2023

Patent: 4,617,271


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 4,617,271
Title: Process for producing immobilized L-asparaginase preparations for the therapy of leukemia
Abstract:This invention relates to a process for producing immobilized L-asparaginase preparations. Its principal object is to produce immobilized L-asparaginase preparations which are excellent in antithrombogenicity and mechanical strength. The present invention is concerned with production of immobilized L-asparaginase preparations by pouring an aqueous solution containing 6% or more of a polyvinyl alcohol with a degree of hydrolysis of 97 mol. % or higher and a viscosity-average degree of polymerization of 1,800 or more an antileukemic asparaginase into a vessel or a mold of an appropriate shape, subjecting the solution to cooling, solidification and molding at a temperature of -15.degree. C. or lower and partially dehydrating the molded mass without thawing to a dehydration ratio of 5% by weight or more and, if desired, immersing the product in water. According to the invention, L-asparaginase can be embedded in a highly hydrous gel excellent in antithrombogenicity and mechanical strength by simple procedures.
Inventor(s): Nambu; Masao (Yokohama, JP)
Assignee: Nippon Oil Company, Limited (Tokyo, JP)
Application Number:06/573,922
Patent Claims:see list of patent claims

Details for Patent 4,617,271

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 01/10/1978 See Plans and Pricing 2003-10-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Medtronic
McKesson
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.